NANOVIRICIDES, INC. Deferred Compensation Arrangement with Individual, Compensation Expense
NANOVIRICIDES, INC. (NNVC) reported Deferred Compensation Arrangement with Individual, Compensation Expense of $400.00 thousand for the 12-month period ending 2020-06-30, per its 10-K filed 2020-10-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense · last filed 2020-10-13
- NANOVIRICIDES, INC. deferred compensation arrangement with individual, compensation expense for the quarter ending 2020-06-30 was $0.00.
- NANOVIRICIDES, INC. deferred compensation arrangement with individual, compensation expense for the quarter ending 2020-03-31 was $0.00.
- NANOVIRICIDES, INC. deferred compensation arrangement with individual, compensation expense for the quarter ending 2019-12-31 was $0.00.
- NANOVIRICIDES, INC. deferred compensation arrangement with individual, compensation expense for the quarter ending 2019-09-30 was $400.00K, a 0.00% change year-over-year.
- NANOVIRICIDES, INC. deferred compensation arrangement with individual, compensation expense for fiscal 2020 was $400.00K, a 0.00% change from fiscal 2019.
- NANOVIRICIDES, INC. deferred compensation arrangement with individual, compensation expense for fiscal 2019 was $400.00K.
| Period end | Deferred Compensation Arrangement with Individual, Compensation Expense 3 month | Deferred Compensation Arrangement with Individual, Compensation Expense 6 month | Deferred Compensation Arrangement with Individual, Compensation Expense 9 month | Deferred Compensation Arrangement with Individual, Compensation Expense 12 month |
|---|---|---|---|---|
| 2020-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-13 | $0.00 derived: sum of 2 quarters · filed 2020-10-13 | $0.00 derived: sum of 3 quarters · filed 2020-10-13 | $400.00K 10-K · filed 2020-10-13 |
| 2020-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-06-22 | $0.00 derived: sum of 2 quarters · filed 2020-06-22 | $400.00K 10-Q · filed 2020-06-22 | $400.00K derived: sum of 4 quarters · filed 2020-06-22 |
| 2019-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-14 | $400.00K 10-Q · filed 2020-02-14 | $400.00K derived: sum of 3 quarters · filed 2020-02-14 | $400.00K derived: sum of 4 quarters · filed 2020-02-14 |
| 2019-09-30 | $400.00K 10-Q · filed 2019-11-15 | $400.00K derived: sum of 2 quarters · filed 2019-11-15 | $400.00K derived: sum of 3 quarters · filed 2019-11-15 | $400.00K derived: sum of 4 quarters · filed 2019-11-15 |
| 2019-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-08-23 | $0.00 derived: sum of 2 quarters · filed 2019-08-23 | $0.00 derived: sum of 3 quarters · filed 2019-08-23 | $400.00K 10-K · filed 2019-08-23 |
| 2019-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-15 | $0.00 derived: sum of 2 quarters · filed 2019-05-15 | $400.00K 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-14 | $400.00K 10-Q · filed 2019-02-14 | ||
| 2018-09-30 | $400.00K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |